California-based C3 Jian has signed an agreement with the West China School of Stomatology at Sichuan University (“West China”) to create a joint clinical research center to test new oral healthcare products in human clinical trials. It will be located at West China’s facilities in Chengdu, China. The research center will operate under U.S. FDA’s GCP.
C3 Jian expects the first clinical trial undertaken at the clinical research center will be directed toward its Sm STAMPS product targeting dental caries. Dental caries are a multibillion-dollar annual burden on healthcare systems worldwide. In the U.S. alone, annual dental expenditures related to the bacteria that causes dental caries is estimated to exceed $50 billion. It is also a significant problem in China. C3 Jian is developing the first specifically targeted drug to eliminate dental caries. The product is expected to be administered in the form of a mouth wash.